Schizophrenia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who are covered by a social security or other social protection scheme
- People who have been diagnosed with schizophrenia according to the DSM-5 standard (diagnostic code F20)
- People whose condition is currently in a stable state (no specific time period required for this stability)
- People whose main antipsychotic medication is risperidone, paliperidone, aripiprazole, or olanzapine, taken either as a daily oral tablet or as a long-acting injectable
- People who are also taking chlorpromazine, loxapine, or cyamemazine as an additional medication for anxiety or sedation
- People who are able to speak and read French
- People who are able to take part in speech-based assessments
- People who are able to answer questionnaires on a smartphone
- People who are under a legal guardianship or curatorship arrangement may still be considered
- People who agree to take part and have signed an informed consent form, with a legal representative also signing if the person is under guardianship or curatorship
Who may not be able to join:
- People who have a condition that affects their ability to use the French language
- People who have a neurological condition such as multiple sclerosis, Parkinson's disease, Huntington's disease, or any other neurodegenerative disease
- People who are currently taking lithium salts as part of their treatment
- People who are currently taking anti-epileptic medication
- People who are already taking part in another clinical trial that involves medication
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Pierre De Maricourt, Dr, GHU Paris Psychiatry & Neurosciences
Phone: (0)1 45 65 86 91
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Voice interviews recorded on Callyope application; Plasma concentration of antipsychotics
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.